LOW LDL DOES NOT PROTECT, BUT BIG PHARMA AND HARVARD SAY YES

by | Jun 27, 2017 | Antioxidants, Big Pharma, Cancer, Cardiovascular Disease, Inflammation, Sugar

Amgen, the maker of evolocumab (Repatha) funded the research, paid EVERY author on the paper, led by Harvard researchers, and the findings were published in the prestigious New England Journal of Medicine May 4, 2017. If you take the drug, evolocumab (Repatha), your LDL will go down but you won’t live any longer. IT’S ALL ABOUT INFLAMMATION AND OXIDATION.